You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Resected

Showing 1 - 25 of 2,877
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial (ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab)

Not yet recruiting
  • Melanoma
  • ABP 206
  • +2 more
  • (no location specified)
Jun 8, 2023

Pancreatic Cancer Trial in Shanghai (Adebrelimab, mRNA tumor vaccines)

Not yet recruiting
  • Pancreatic Cancer
  • Shanghai, Shanghai, China
    Department of Pancreatic Surgery, Fudan University Shanghai Canc
Dec 4, 2023

Identify Resected Non-small-cell Lung Cancer With High Risk of

Recruiting
  • Non-small Cell Lung Cancer Stage IIIA
  • Resected non small cell lung cancer
  • Toulouse, France
    Julien MAZIERES
Feb 8, 2023

Pancreatic Cancer, Resectable Carcinoma Trial in Beijing (Later-line therapy)

Recruiting
  • Pancreatic Cancer
  • Resectable Carcinoma
  • Later-line therapy
  • Beijing, China
    Department of Medical Oncology, Peking Union Medical College Hos
Apr 10, 2023

Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01 in combination with standard adjuvant therapy)

Recruiting
  • Digestive System Neoplasms
  • iNeo-Vac-R01 in combination with standard adjuvant therapy
  • Hangzhou, Zhejiang, China
    Department of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023

NSCLC Trial in Shanghai

Not yet recruiting
  • Non-small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Jul 20, 2023

    NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

    Recruiting
    • Non-small Cell Lung Cancer
    • SH-1028 tablets
    • Placebo SH-1028 tablets
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Oct 6, 2023

    Pancreatic Cancer Trial in United States (Gemcitabine and Capecitabine)

    Recruiting
    • Pancreatic Cancer
    • Gemcitabine and Capecitabine
    • New Brunswick, New Jersey
      Rutgers Cancer Institute of New Jersey
    Dec 31, 2022

    Adenocarcinoma, Pancreatic Ductal Trial in New York (Autogene cevumeran, Atezolizumab, mFOLFIRINOX)

    Recruiting
    • Adenocarcinoma, Pancreatic Ductal
    • Autogene cevumeran
    • +2 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jul 21, 2023

    Novel Grading System of Resected Lung Adenocarcinoma

    Recruiting
    • Lung Adenocarcinoma
    • +2 more
    • Whole Slide Image based Deep Learning Signature
    • Zunyi, Guizhou, China
    • +2 more
    Jun 27, 2023

    Resectable Head and Neck Squamous Cell Carcinoma Trial in Milwaukee (42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy

    Suspended
    • Resectable Head and Neck Squamous Cell Carcinoma
    • 42 Gy Radiation Therapy
    • +2 more
    • Milwaukee, Wisconsin
      Froedtert & the Medical College of Wisconsin
    Jan 13, 2023

    Resectable Lung Non-Small Cell Carcinoma Trial in Atlanta (procedure, radiation, other)

    Not yet recruiting
    • Resectable Lung Non-Small Cell Carcinoma
    • Biospecimen Collection
    • +2 more
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    Aug 22, 2023

    Aggressive Histological Pattern in Resected Non-small Cell Lung

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • PET/CT-based Deep Learning Signature
    • Zunyi, Guizhou, China
    • +2 more
    Jun 27, 2023

    Brain Metastases, Brain Cancer Trial in Miami (18F-Fluciclovine)

    Not yet recruiting
    • Brain Metastases
    • Brain Cancer
    • Miami, Florida
      Miami Cancer Institute at Baptist Health South Florida
    Jan 3, 2023

    Clinical Stage IIA Cutaneous Melanoma AJCC v8 Trial in Portland (drug, procedure, other)

    Not yet recruiting
    • Clinical Stage IIA Cutaneous Melanoma AJCC v8
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Nov 27, 2023

    Resected Pancreatic Adenocarcinoma

    Completed
    • Pancreatic Cancer Resectable
    • Multigene panel for next-generation sequencing
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Jul 31, 2022

    ctDNA-based Minimal Residual Disease Detection for Resected

    Not yet recruiting
    • Pancreatic Cancer Resectable
    • ctDNA-based MRD detection
    • Shanghai, Shanghai, China
      Ruijin Hospital Affiliated to Shanghai Jiao Tong University Scho
    Jul 29, 2022

    Peritoneum Cancer, Peritoneal Carcinomatosis, Peritoneal Metastases Trial in Odense (PIPAC)

    Recruiting
    • Peritoneum Cancer
    • +3 more
    • Odense, Denmark
      Odense PIPAC Center, Department of Surgery, Odense University Ho
    Oct 5, 2022

    Multi-Platform Profiling of Resected Biliary Tract Cancer

    Recruiting
    • Biliary Tract Cancer
    • +7 more
    • Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
    • Chicago, Illinois
    • +1 more
    Jan 23, 2023

    Melanoma Trial in Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

    Recruiting
    • Melanoma
    • Knoxville, Tennessee
      University of Tennessee Medical Center
    Dec 20, 2022

    RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL

    Recruiting
    • the Records of Esophageal Cancer
    • Since the data were collected retrospectively, there were no interventions
    • Chendu, Sichuan, China
      Sichuan Cancer Hospital
    Oct 24, 2022

    Nsclc Trial in Montpellier (Blood sample)

    Recruiting
    • Nsclc
    • Blood sample
    • Montpellier, France
      University Hospital
    Apr 27, 2022

    Pancreatic Cancer Trial in Providence (FOLFOXA)

    Completed
    Has Results
    • Pancreatic Cancer
    • Providence, Rhode Island
    • +1 more
    May 12, 2022

    Soft Tissue Sarcoma Trial in France (Prevena)

    Not yet recruiting
    • Soft Tissue Sarcoma
    • Prevena
    • Nantes, Pays De Loire, France
    • +12 more
    Jul 12, 2023

    NSCLC, Stage I Trial (Tislelizumab monotherapy)

    Not yet recruiting
    • NSCLC, Stage I
    • Tislelizumab monotherapy
    • (no location specified)
    Mar 9, 2022